Macular Disease Foundation Australia logo

    Webinar: Detection of neovascular AMD with OCT and OCT-A

    Presented by Professor Paul Mitchell AO

    This webinar, aimed at eye health care professionals, explores the detection of neovascular age-related macular degeneration (AMD) with optical coherence tomography (OCT) and optical coherence tomography angiography (OCT-A).

    At the end of the webinar you should be able to:

    • Describe and identify the prognostic biomarkers that may indicate an increased risk of progression of intermediate AMD.
    • Identify and evaluate neovascular changes in AMD with OCT and colour retinal photography.
    • Identity additional insights OCT-A can provide in neovascular AMD diagnosis.

    About the presenter:

    Professor Paul Mitchell AO is the Director of the Centre For Vision Research at The Westmead Institute for Medical Research. He is currently an (Emeritus) Professor of Ophthalmology at the University of Sydney (Westmead Hospital). He works clinically as a medical retina specialist at Sydney West Retina in Westmead, and at Westmead Hospital. His clinical focus is on managing AMD, diabetic retinopathy, and other vascular retinopathies and the effects of systemic diseases on the eye. 

    Paul has made significant contributions in the fields of public health and ophthalmic epidemiology via the landmark Blue Mountains Eye Study, with papers in all major eye journals, as well as leading medical journals, including NEJM and Lancet. He has also conducted considerable research into childhood eye conditions via the Sydney Childhood Eye Study. 

    He has co-authored over 1,100 papers in peer-reviewed journals and 75 books, chapters, or letters. To date, he has supervised 25 completed PhD students as primary supervisor. He is among the most cited ophthalmologists in Australia, with 90,000 citations to his published work to date. Total career research funding exceeds $30 million. He is involved in many Australian and International collaborative studies, including large-scale genetic and population pooling projects. His team will conduct the 2nd National Eye Health Study, commencing in late 2021.